Cyclacel Q3: net loss $5.1M, cash $23.7M; oral fadraciclib shows 2 partial responses in T-cell lymphoma

Bio Green Med Solution, Inc.

2022-Q3 EPS reported -$1.29

Cash $23.7M at Sept 30, 2022 (vs $36.6M at Dec 31, 2021); cash runway expected to fund programs to end of 2023.
Oral fadraciclib Phase 1/2: 18 evaluable patients; 2/3 partial responses in T-cell lymphoma, 11 stable diseases across solid tumors.
Oral CYC140 Phase 1/2: no DLTs; durable stable disease at first dose level in ovarian and KRAS G12V NSCLC patients.
Terminating sapacitabine license with Daiichi Sankyo, effective March 23, 2023; not pursuing further development.
Expect to determine RP2D for fadraciclib in 4Q 2022 and start Phase 2 in 1H 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Bio Green Med Solution, Inc. reported financial results for the third quarter ended September 30, 2022.

Period: the third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

a copy of a press release of Cyclacel Pharmaceuticals, Inc. (the “ Company ”), dated November 9, 2022, announcing certain financial results for the third quarter ended September 30, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Bio Green Med Solution, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-116489

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.